The Progressive Supranuclear Palsy Clinical Trial Platform

Part of paid clinical trials in San Francisco, California.

Sponsor
Adam Boxer
Study ID
NCT07173803
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Progressive Supranuclear Palsy(PSP)

Eligibility Criteria

Sex
ALL
Age
41 Years - 86 Years
Healthy Volunteers
Not accepted

Interventions

  • AADvac1 — BIOLOGICAL
    Active immunotherapy
  • LM11A-31 — DRUG
    Small molecule

Study Details

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.

Key Dates

First listed
Sep 15, 2025
Start date
Jun 30, 2026
Status verified
Nov 2025
Primary completion
Sep 28, 2030
Completion
Sep 28, 2030

Study Design

Enrollment
440 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Regimen A: AADvac1
    Participants are randomized to receive either active AADvac1 or matching placebo.
  • Experimental: Regimen B: LM11A-31
    Participants are randomized to receive either active LM11A-31 or matching placebo.

Primary Outcome Measure

Disease progression [ Time Frame: 52 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94158
Julio Rojas-Martinez, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CA

Related Studies